|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.5 EUR | +0.37% |
|
+3.05% | +1.40% |
| May. 02 | DANONE : UBS keeps its Buy rating | ZD |
| May. 02 | Danone: acquisition of Functional Formularies | CF |
| Entry price | Target | Stop-loss | Potential |
|---|---|---|---|
| €54.42 | €57.5 | €52 | +5.66% |
● According to Refinitiv, the company's ESG score for its industry is good.
● The company's profit outlook over the next few years is a strong asset.
● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.40% | 41.13B | |
| -2.39% | 275B | |
| -1.70% | 95.5B | |
| -2.00% | 44.01B | |
| +9.84% | 41.41B | |
| +8.54% | 39.91B | |
| -12.79% | 31.14B | |
| -4.77% | 29.23B | |
| +14.15% | 25.25B | |
| -4.34% | 23.96B |
DANONE 
